• 2X Taq PCR Master Mix: Streamlining Genotyping and TA Clonin

  2026-07-23

  Accelerate molecular workflows with the 2X Taq PCR Master Mix (with dye) from APExBIO—engineered for robust DNA amplification, seamless direct gel loading, and superior compatibility with TA cloning. Learn how its ready-to-use formulation and built-in dye reduce errors, enhance reproducibility, and empower translational research.

• Intestinal TM6SF2 Deficiency Drives MASH via the Gut–Liver A

  2026-07-23

  This study identifies intestinal TM6SF2 as a critical protector against metabolic dysfunction-associated steatohepatitis (MASH), linking its deficiency to gut barrier impairment, microbial dysbiosis, and hepatic inflammation. By dissecting the mechanistic role of lipid signaling via the gut–liver axis, the research opens new experimental avenues for targeting metabolic liver disease.

• 2X Taq PCR Master Mix: Applied Workflows for Genotyping & Cl

  2026-07-22

  Leverage the 2X Taq PCR Master Mix (with dye) for streamlined genotyping, direct-to-gel analysis, and TA cloning. This article bridges experimental virology with practical PCR optimization, distilling troubleshooting insights and real-world protocol enhancements.

• URB597 (KDS-4103): Unleashing FAAH Inhibition in Translation

  2026-07-22

  Explore how URB597 (KDS-4103), a potent and selective FAAH inhibitor, is redefining translational pain research by enabling precise endocannabinoid modulation. This article bridges mechanistic insights with actionable guidance, contextualizing APExBIO's URB597 against evolving neuroinflammation and orofacial pain paradigms, and highlighting where this tool uniquely advances the field beyond conventional product pages.

• IGF2BP3–FZD1/7 Axis Drives Stemness and Platinum Resistance

  2026-07-21

  This study identifies IGF2BP3 as a key m6A reader stabilizing FZD1/7 mRNAs, which enhances cancer stem-like properties and carboplatin resistance in triple-negative breast cancer (TNBC). Targeting this axis, either genetically or pharmacologically, represents a promising strategy to sensitize TNBC cells to chemotherapy and potentially improve clinical outcomes.

• DAPT (GSI-IX): Optimizing Notch Pathway Studies in Applied R

  2026-07-21

  DAPT (GSI-IX) is redefining the precision available to researchers dissecting Notch signaling, amyloid processing, and cell fate determination. This guide details actionable protocols, troubleshooting strategies, and translational insights for maximizing assay reliability and biological relevance in neurodegeneration and beyond.

• 2,5-di-tert-butylbenzene-1,4-diol: Advancing SERCA Inhibitio

  2026-07-20

  2,5-di-tert-butylbenzene-1,4-diol (BHQ) is redefining calcium signaling research and stem cell mobilization through selective SERCA inhibition. Discover workflow-optimized strategies and troubleshooting insights that translate cutting-edge findings into robust, reproducible experimental outcomes.

• Carfilzomib (PR-171): Advanced Protocols for Proteasome Inhi

  2026-07-20

  Carfilzomib (PR-171) is redefining proteasome inhibition in cancer research with its potent, irreversible action and optimized experimental flexibility. This article delivers actionable workflows, troubleshooting insights, and strategic integration tips for maximizing its translational impact.

• RNA Clean and Concentrator Kit: Data-Driven Lab Reliability

  2026-07-19

  This article explores real-world laboratory challenges in RNA purification and demonstrates how the RNA Clean and Concentrator Kit (SKU K1069) streamlines workflows, ensures sample integrity, and enables reproducible results. Drawing on quantitative data and scenario-based analysis, we clarify how the kit supports high-throughput, sensitive applications in biomedical research.

• Spatially Concentrated Base Editors Correct PLP1 Mutations i

  2026-07-18

  This study presents a spatially concentrated adenine base editor (cABE) system that achieves efficient correction of PLP1 A243V mutations in oligodendrocytes, addressing a major barrier in gene therapy for Pelizaeus–Merzbacher disease. The work demonstrates that nuclear enrichment and phase separation of base editors, rather than catalytic enhancement, can drive precision editing in hard-to-target CNS cell types.

• Deoxynivalenol Liver Injury: Mitophagy and Nrf2 Pathway Disr

  2026-07-17

  This study elucidates how deoxynivalenol (DON), a pervasive mycotoxin, induces liver injury through overactivation of PINK1/Parkin-mediated mitophagy and suppression of the p62-Keap1-Nrf2 cytoprotective pathway. These mechanistic insights offer a foundation for improved hepatotoxicity models and highlight potential molecular targets for intervention.

• Olaparib (AZD2281): Optimizing DNA Damage Response Assays

  2026-07-17

  Olaparib (AZD2281) enables precise interrogation of homologous recombination repair defects for targeted cancer research, especially in BRCA-deficient and BRCAness models. This guide translates recent experimental advances into actionable protocols, troubleshooting strategies, and workflow enhancements for tumor radiosensitization and combination therapy studies.

• Deferoxamine Mesylate: Iron-Chelating Agent for Advanced Res

  2026-07-16

  Deferoxamine mesylate stands out as an iron-chelating agent, uniquely enabling precision studies of hypoxia, oxidative stress, and tumor biology. Discover how its robust solubility, HIF-1α stabilization, and workflow flexibility empower experimental breakthroughs across cancer, metabolism, and tissue protection models.

• ARCA EGFP mRNA (5-moUTP): Unraveling Polyadenylated mRNA for

  2026-07-16

  Explore how ARCA EGFP mRNA (5-moUTP) elevates polyadenylated mRNA transfection with unmatched fluorescence-based sensitivity and minimized immune activation. This article uniquely bridges storage optimization science with advanced control assay design.

• Mitocytosis Inhibition Enhances Mitochondrial Drug Delivery

  2026-07-15

  The reference study reveals that inhibiting mitocytosis—a process that expels damaged mitochondria via migrasomes—markedly improves the efficacy of mitochondria-targeted therapies in metastatic breast cancer models. By engineering a dual-targeted nanoplatform that combines mitochondrial damage with mitocytosis blockade, the research establishes a new strategy to overcome resistance in antimetastatic treatment.

14550 records 1/970 page Next 12345 下5页 Last page